

# Li-Shiun Chen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/843377/publications.pdf>

Version: 2024-02-01

76  
papers

3,081  
citations

186265

28  
h-index

182427

51  
g-index

78  
all docs

78  
docs citations

78  
times ranked

5192  
citing authors

#	ARTICLE	IF	CITATIONS
1	Point of care tobacco treatment sustains during COVID-19, a global pandemic. <i>Cancer Epidemiology</i> , 2022, 78, 102005.	1.9	8
2	Quantifying rural disparity in healthcare utilization in the United States: Analysis of a large midwestern healthcare system. <i>PLoS ONE</i> , 2022, 17, e0263718.	2.5	16
3	The Promise of Polygenic Risk Prediction in Smoking Cessation: Evidence From Two Treatment Trials. <i>Nicotine and Tobacco Research</i> , 2022, 24, 1573-1580.	2.6	10
4	The Impact of Persistent Smoking After Surgery on Long-term Outcomes After Stage I Non-small Cell Lung Cancer Resection. <i>Chest</i> , 2022, 161, 1687-1696.	0.8	13
5	Increased Reach and Effectiveness With a Low-Burden Point-of-Care Tobacco Treatment Program in Cancer Clinics. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 488-495.e4.	4.9	3
6	Exploring How Social Media Exposure and Interactions Are Associated With ENDS and Tobacco Use in Adolescents From the PATH Study. <i>Nicotine and Tobacco Research</i> , 2021, 23, 487-494.	2.6	25
7	Shared genetic risk between eating disorder and substance use-related phenotypes: Evidence from genome-wide association studies. <i>Addiction Biology</i> , 2021, 26, e12880.	2.6	28
8	Mixed-methods economic evaluation of the implementation of tobacco treatment programs in National Cancer Institute-designated cancer centers. <i>Implementation Science Communications</i> , 2021, 2, 41.	2.2	18
9	Tobacco Treatment Program Models in US Hospitals and Outpatient Centers on Behalf of the SRNT Treatment Network. <i>Chest</i> , 2021, 159, 1652-1663.	0.8	10
10	Racial disparities in intensity of smoke exposure and nicotine intake among low-dependence smokers. <i>Drug and Alcohol Dependence</i> , 2021, 221, 108641.	3.2	3
11	Studying the Utility of Using Genetics to Predict Smoking-Related Outcomes in a Population-Based Study and a Selected Cohort. <i>Nicotine and Tobacco Research</i> , 2021, 23, 2110-2116.	2.6	6
12	Review and Consensus on Pharmacogenomic Testing in Psychiatry. <i>Pharmacopsychiatry</i> , 2021, 54, 5-17.	3.3	96
13	Proof of Concept of a Personalized Genetic Risk Tool to Promote Smoking Cessation: High Acceptability and Reduced Cigarette Smoking. <i>Cancer Prevention Research</i> , 2021, 14, 253-262.	1.5	6
14	Care-paradigm shift promoting smoking cessation treatment among cancer center patients via a low-burden strategy, Electronic Health Record-Enabled Evidence-Based Smoking Cessation Treatment. <i>Translational Behavioral Medicine</i> , 2020, 10, 1504-1514.	2.4	29
15	Variants in the CHRNA5-CHRNA3-CHRNA4 Region of Chromosome 15 Predict Gastrointestinal Adverse Events in the Transdisciplinary Tobacco Use Research Center Smoking Cessation Trial. <i>Nicotine and Tobacco Research</i> , 2020, 22, 248-255.	2.6	4
16	Changes in alcohol and cigarette consumption in response to medical and recreational cannabis legalization: Evidence from U.S. state tax receipt data. <i>International Journal of Drug Policy</i> , 2020, 75, 102585.	3.3	26
17	A large-scale genome-wide association study meta-analysis of cannabis use disorder. <i>Lancet Psychiatry</i> , 2020, 7, 1032-1045.	7.4	200
18	Dissecting the genetic overlap of smoking behaviors, lung cancer, and chronic obstructive pulmonary disease: A focus on nicotinic receptors and nicotine metabolizing enzyme. <i>Genetic Epidemiology</i> , 2020, 44, 748-758.	1.3	7

#	ARTICLE	IF	CITATIONS
19	Participatory Design of a Personalized Genetic Risk Tool to Promote Behavioral Health. <i>Cancer Prevention Research</i> , 2020, 13, 583-592.	1.5	6
20	Low Burden Strategies Are Needed to Reduce Smoking in Rural Healthcare Settings: A Lesson from Cancer Clinics. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 1728.	2.6	21
21	Genetic Variant in CHRNA5 and Response to Varenicline and Combination Nicotine Replacement in a Randomized Placebo-Controlled Trial. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 1315-1325.	4.7	17
22	Pragmatic Application of the RE-AIM Framework to Evaluate the Implementation of Tobacco Cessation Programs Within NCI-Designated Cancer Centers. <i>Frontiers in Public Health</i> , 2020, 8, 221.	2.7	30
23	Tobacco Genomics: Complexity and Translational Challenges. <i>Nicotine and Tobacco Research</i> , 2019, 21, 705-706.	2.6	2
24	Leverage points to improve smoking cessation treatment in a large tertiary care hospital: a systems-based mixed methods study. <i>BMJ Open</i> , 2019, 9, e030066.	1.9	13
25	Determining population stratification and subgroup effects in association studies of rare genetic variants for nicotine dependence. <i>Psychiatric Genetics</i> , 2019, 29, 111-119.	1.1	1
26	E-cigarette Usage Is Associated With Increased Past-12-Month Quit Attempts and Successful Smoking Cessation in Two US Population-Based Surveys. <i>Nicotine and Tobacco Research</i> , 2019, 21, 1331-1338.	2.6	43
27	Tobacco Use Prevalence and Smoking Cessation Pharmacotherapy Prescription Patterns Among Hospitalized Patients by Medical Specialty. <i>Nicotine and Tobacco Research</i> , 2019, 21, 631-637.	2.6	11
28	Toward the implementation of genomic applications for smoking cessation and smoking-related diseases. <i>Translational Behavioral Medicine</i> , 2018, 8, 7-17.	2.4	12
29	Smoking Interacts With CHRNA5, a Nicotinic Acetylcholine Receptor Subunit Gene, to Influence the Risk of IBD-Related Surgery. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 1057-1064.	1.9	7
30	Pathways to precision medicine in smoking cessation treatments. <i>Neuroscience Letters</i> , 2018, 669, 83-92.	2.1	47
31	<i>CYP2A6</i> metabolism in the development of smoking behaviors in young adults. <i>Addiction Biology</i> , 2018, 23, 437-447.	2.6	10
32	The Value of Biosamples in Smoking Cessation Trials: A Review of Genetic, Metabolomic, and Epigenetic Findings. <i>Nicotine and Tobacco Research</i> , 2018, 20, 403-413.	2.6	16
33	Leveraging Genomic Data in Smoking Cessation Trials in the Era of Precision Medicine: Why and How. <i>Nicotine and Tobacco Research</i> , 2018, 20, 414-424.	2.6	15
34	Genetic correlation between smoking behaviors and schizophrenia. <i>Schizophrenia Research</i> , 2018, 194, 86-90.	2.0	71
35	Genome-Wide Association Study of Heavy Smoking and Daily/Nondaily Smoking in the Hispanic Community Health Study/Study of Latinos (HCHS/SOL). <i>Nicotine and Tobacco Research</i> , 2018, 20, 448-457.	2.6	21
36	Finding paths with the greatest chance of success: enabling and focusing lung cancer screening and cessation in resource-constrained areas. <i>Translational Lung Cancer Research</i> , 2018, 7, S261-S264.	2.8	0

#	ARTICLE	IF	CITATIONS
37	Transancestral GWAS of alcohol dependence reveals common genetic underpinnings with psychiatric disorders. <i>Nature Neuroscience</i> , 2018, 21, 1656-1669.	14.8	490
38	Use of polygenic risk scores of nicotine metabolism in predicting smoking behaviors. <i>Pharmacogenomics</i> , 2018, 19, 1383-1394.	1.3	13
39	Most Current Smokers Desire Genetic Susceptibility Testing and Genetically-Efficacious Medication. <i>Journal of NeuroImmune Pharmacology</i> , 2018, 13, 430-437.	4.1	11
40	Low-Burden Strategies to Promote Smoking Cessation Treatment Among Patients With Serious Mental Illness. <i>Psychiatric Services</i> , 2018, 69, 849-851.	2.0	11
41	From genes to treatments: a systematic review of the pharmacogenetics in smoking cessation. <i>Pharmacogenomics</i> , 2018, 19, 861-871.	1.3	16
42	Association Between Substance Use Disorder and Polygenic Liability to Schizophrenia. <i>Biological Psychiatry</i> , 2017, 82, 709-715.	1.3	62
43	Smoking Cessation and Electronic Cigarettes in Community Mental Health Centers: Patient and Provider Perspectives. <i>Community Mental Health Journal</i> , 2017, 53, 695-702.	2.0	33
44	Task-related fMRI responses to a nicotinic acetylcholine receptor partial agonist in schizophrenia: A randomized trial. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2016, 71, 66-75.	4.8	8
45	Genetic Risk Can Be Decreased: Quitting Smoking Decreases and Delays Lung Cancer for Smokers With High and Low CHRNA5 Risk Genotypes – A Meta-Analysis. <i>EBioMedicine</i> , 2016, 11, 219-226.	6.1	40
46	Association of the OPRM1 Variant rs1799971 (A118G) with Non-Specific Liability to Substance Dependence in a Collaborative de novo Meta-Analysis of European-Ancestry Cohorts. <i>Behavior Genetics</i> , 2016, 46, 151-169.	2.1	98
47	Associations between smoking behavior-related alleles and the risk of melanoma. <i>Oncotarget</i> , 2016, 7, 47366-47375.	1.8	15
48	The value of control conditions for evaluating pharmacogenetic effects. <i>Pharmacogenomics</i> , 2015, 16, 2005-2006.	1.3	2
49	Identification of Medically Actionable Secondary Findings in the 1000 Genomes. <i>PLoS ONE</i> , 2015, 10, e0135193.	2.5	74
50	When Does Choice of Accuracy Measure Alter Imputation Accuracy Assessments?. <i>PLoS ONE</i> , 2015, 10, e0137601.	2.5	25
51	Genetic variation (CHRNA5), medication (combination nicotine replacement therapy vs. varenicline), and smoking cessation. <i>Drug and Alcohol Dependence</i> , 2015, 154, 278-282.	3.2	38
52	CHRNA5 Risk Variant Predicts Delayed Smoking Cessation and Earlier Lung Cancer Diagnosis – A Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	6.3	72
53	Return of individual genetic results in a high-risk sample: enthusiasm and positive behavioral change. <i>Genetics in Medicine</i> , 2015, 17, 374-379.	2.4	29
54	Beyond Cigarettes Per Day. A Genome-Wide Association Study of the Biomarker Carbon Monoxide. <i>Annals of the American Thoracic Society</i> , 2014, 11, 1003-1010.	3.2	35

#	ARTICLE	IF	CITATIONS
55	CHRNA5 Variant Predicts Smoking Cessation in Patients With Acute Myocardial Infarction. <i>Nicotine and Tobacco Research</i> , 2014, 16, 1224-1231.	2.6	25
56	Variants in two adjacent genes, EGLN2 and CYP2A6, influence smoking behavior related to disease risk via different mechanisms. <i>Human Molecular Genetics</i> , 2014, 23, 555-561.	2.9	35
57	Pharmacotherapy effects on smoking cessation vary with nicotine metabolism gene ( <i>CYP2A6</i> ). <i>Addiction</i> , 2014, 109, 128-137.	3.3	75
58	Interplay of genetic risk (CHRNA5) and environmental risk (partner smoking) on cigarette smoking reduction. <i>Drug and Alcohol Dependence</i> , 2014, 143, 36-43.	3.2	17
59	Genomics and personalized medicine: CHRNA5-CHRNA3-CHRNA4 and smoking cessation treatment. <i>Journal of Food and Drug Analysis</i> , 2013, 21, S87-S90.	1.9	22
60	Genetics and pharmacogenetics of substance use disorders. <i>Journal of Food and Drug Analysis</i> , 2013, 21, S23-S24.	1.9	0
61	CYP2B6 Non-Coding Variation Associated with Smoking Cessation Is Also Associated with Differences in Allelic Expression, Splicing, and Nicotine Metabolism Independent of Common Amino-Acid Changes. <i>PLoS ONE</i> , 2013, 8, e79700.	2.5	18
62	Response to Kaufman and Harper Letter. <i>American Journal of Psychiatry</i> , 2012, 169, 1118-1119.	7.2	2
63	Nicotine dependence and comorbid psychiatric disorders: Examination of specific genetic variants in the CHRNA5-A3-B4 nicotinic receptor genes. <i>Drug and Alcohol Dependence</i> , 2012, 123, S42-S51.	3.2	13
64	Interplay of Genetic Risk Factors (CHRNA5-CHRNA3-CHRNA4) and Cessation Treatments in Smoking Cessation Success. <i>American Journal of Psychiatry</i> , 2012, 169, 735-742.	7.2	138
65	Smoking and Genetic Risk Variation Across Populations of European, Asian, and African American Ancestry: A Meta-Analysis of Chromosome 15q25. <i>Genetic Epidemiology</i> , 2012, 36, 340-351.	1.3	69
66	Dissection of the Phenotypic and Genotypic Associations With Nicotinic Dependence. <i>Nicotine and Tobacco Research</i> , 2011, 14, 425-433.	2.6	42
67	Peer smoking and the nicotinic receptor genes: an examination of genetic and environmental risks for nicotine dependence. <i>Addiction</i> , 2010, 105, 2014-2022.	3.3	56
68	GENETIC STUDY: FULL ARTICLE: Incorporating age at onset of smoking into genetic models for nicotine dependence: evidence for interaction with multiple genes. <i>Addiction Biology</i> , 2010, 15, 346-357.	2.6	41
69	Interplay of genetic risk factors and parent monitoring in risk for nicotine dependence. <i>Addiction</i> , 2009, 104, 1731-1740.	3.3	69
70	Familial aggregation of clinical and neurocognitive features in sibling pairs with and without schizophrenia. <i>Schizophrenia Research</i> , 2009, 111, 159-166.	2.0	35
71	Agoraphobia in adults: Incidence and longitudinal relationship with panic. <i>British Journal of Psychiatry</i> , 2006, 188, 432-438.	2.8	54
72	Incidence rates for alcohol dependence among adults: prospective data from the Baltimore Epidemiologic Catchment Area Follow-Up Survey, 1981-1996. <i>Journal of Studies on Alcohol and Drugs</i> , 2005, 66, 795-805.	2.3	23

#	ARTICLE	IF	CITATIONS
73	Understanding the heterogeneity of depression through the triad of symptoms, course and risk factors: a longitudinal, population-based study. <i>Journal of Affective Disorders</i> , 2000, 59, 1-11.	4.1	138
74	Cognitive Decline in Adulthood: An 11.5-Year Follow-Up of the Baltimore Epidemiologic Catchment Area Study. <i>American Journal of Psychiatry</i> , 1999, 156, 58-65.	7.2	182
75	Perceived Cognitive Competence, Depressive Symptoms and the Incidence of Alcohol-Related Problems in Urban School Children. <i>Journal of Child and Adolescent Substance Abuse</i> , 1999, 8, 37-53.	0.5	26
76	Onset and recovery from panic disorder in the Baltimore Epidemiologic Catchment Area follow-up. <i>British Journal of Psychiatry</i> , 1998, 173, 501-507.	2.8	66